- Home
- GDYN vs ARQT Comparison
GDYN vs ARQT Comparison
Compare GDYN & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDYN
- ARQT
- Stock Information
- Founded
- GDYN 2006
- ARQT 2016
- Country
- GDYN United States
- ARQT United States
- Employees
- GDYN N/A
- ARQT N/A
- Industry
- GDYN Computer Software: Prepackaged Software
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- GDYN Technology
- ARQT Health Care
- Exchange
- GDYN Nasdaq
- ARQT Nasdaq
- Market Cap
- GDYN 1.1B
- ARQT 1.7B
- IPO Year
- GDYN N/A
- ARQT 2020
- Fundamental
- Price
- GDYN $10.83
- ARQT $15.00
- Analyst Decision
- GDYN Strong Buy
- ARQT Strong Buy
- Analyst Count
- GDYN 4
- ARQT 6
- Target Price
- GDYN $18.75
- ARQT $18.80
- AVG Volume (30 Days)
- GDYN 725.9K
- ARQT 2.0M
- Earning Date
- GDYN 07-31-2025
- ARQT 08-13-2025
- Dividend Yield
- GDYN N/A
- ARQT N/A
- EPS Growth
- GDYN 322.00
- ARQT N/A
- EPS
- GDYN 0.13
- ARQT N/A
- Revenue
- GDYN $371,169,000.00
- ARQT $212,819,000.00
- Revenue This Year
- GDYN $21.02
- ARQT $61.15
- Revenue Next Year
- GDYN $13.95
- ARQT $37.98
- P/E Ratio
- GDYN $84.47
- ARQT N/A
- Revenue Growth
- GDYN 18.72
- ARQT 100.03
- 52 Week Low
- GDYN $10.42
- ARQT $7.86
- 52 Week High
- GDYN $25.50
- ARQT $17.75
- Technical
- Relative Strength Index (RSI)
- GDYN 31.01
- ARQT 60.23
- Support Level
- GDYN $11.48
- ARQT $13.06
- Resistance Level
- GDYN $12.86
- ARQT $15.36
- Average True Range (ATR)
- GDYN 0.54
- ARQT 0.66
- MACD
- GDYN 0.01
- ARQT 0.12
- Stochastic Oscillator
- GDYN 1.93
- ARQT 82.57
About GDYN Grid Dynamics Holdings Inc.
Grid Dynamics Holdings Inc is a provider of technology consulting, platform and product engineering, and advanced analytics services. The company delivers tailored solutions in several industry verticals like Tech, Media and Telecom, Retail, Finance and Consumer Packaged goods (CPG)/manufacturing. The company derives maximum revenue from Retails. Geographically company earns revenue from North America, Europe and other regions.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.